ChatGPT:
According to the web search results, the uptake of flibanserin prescriptions in the US in 2022-2023 is not very high. Flibanserin is a drug that was approved by the FDA in 2015 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. However, the drug has been criticized for its low efficacy, high cost, and serious side effects, such as hypotension, syncope, and interactions with alcohol and other medication.
Another web search result estimates that only about 10% of women with HSDD are eligible for flibanserin treatment, based on the criteria of having no medical or mental health problems, no relationship issues, no drug use, and no history of low sexual desire. Furthermore, only about 10% of those eligible women are likely to benefit from flibanserin, based on the clinical trials that showed a modest increase in satisfying sexual events per month (0.5 to 1 more than placebo) and a slight improvement in sexual desire and distress scores. Therefore, the potential market for flibanserin is very limited.
It sounds like a dopamine agonist with the corresponding side effects and they have plenty:
[URL unfurl="true"]https://my.clevelandclinic.org/health/treatments/24958-dopamine-agonists[/URL]
Patient satisfaction is also very low:
a few lucky ones for which it works, the rest is side effects or no effect at all:
[URL unfurl="true"]https://www.drugs.com/comments/flibanserin/for-hypoactive-sexual-desire-disorder.html?search=&sort_reviews=most_recent#reviews[/URL]
